(Alliance News) - Stocks in London are set to kick off the new week on the back foot, as Russia's move to stop gas deliveries to Europe is giving investors pause, amid growing fears of an energy crisis. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its Evusheld Covid-19 treatment was approved in Japan for prevention and treatment of symptomatic disease caused by SARS-CoV-2 infection. Read More
(Alliance News) - AstraZeneca PLC on Saturday said new data show its Farxiga "significantly" lowers the risk of cardiovascular death in patients with heart failure. Read More
(Alliance News) - AstraZeneca PLC on Thursday shared its latest regulatory successes in a key market, winning approvals for three treatments in Japan. Read More
(Alliance News) - AstraZeneca PLC on Wednesday announced it will provide new safety and efficacy data on several of its cancer drugs, purporting to show longer survival for cancer patients. Read More
Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to GBP4.0 million from GBP1.6 million reported the prior 15-month period. Read More
(Alliance News) - The FTSE 100 managed to outperform European counterparts on Friday due to weakness in the pound as consumer confidence in the UK fell to a record low, while attention turns to next week's Jackson Hole Symposium. Read More
(Alliance News) - London's FTSE 100 outperformed peers but was unable to stave off selling pressure in a tough session for European stocks on Friday, despite sitting just above positive territory for much of the late-morning's trade. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its prostate cancer drug candidate Lynparza has received priority review from the US Food & Drug Administration. Read More
(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their Enhertu drug met its primary endpoint in a breast cancer trial. Read More
(Alliance News) - Stock prices in London are seen opening higher on Monday, though equities in China were showing signs of late weakness after poorer than expected retail sales data from the world's second-largest economy. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Friday said their drug conjugate Enhertu has been approved for patients in the US with unresectable or metastatic non-small cell lung cancer. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said results from a trial showed promising clinical activity in patients with non-small cell lung cancer. Read More
(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their drug conjugate Enhertu has been approved for more patients in the US. Read More
